BIO-TECHNE CORP

CEO Kelderman Kim’s November 2026 sale of 2,385 BIO‑TECHNE shares is routine, reflecting stable insider management and a strong sector outlook.

Bio‑Techne insider activity signals cautious bullishness amid Merck’s pending acquisition—gain insights on shares, synergies, and risks for savvy investors.